Reviewer's report

Title: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

Version: Date: 21 April 2005

Reviewer: Brigitta G. Baumert

Reviewer's report:

General
The authors have met nearly all comments of my review. responds to questions were satisfactroy.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

However, there is still one point I woudl like to see being changed, which is the issue on reporting on the corticosteroid dose on Page 4. It is of course known that dexamethasone has a much higher potency, but the sentence as it is written now, is uninformative for the reader. If you recalculate the prednisolone dosis you could say that "Doses ranged between ca 4-5 mg and 40 mg dexamethasone, which still is not very informative. I woudl propose to give the mean equivalent dose of dexamethasone including ranges.

Further, some small things may have slipped during revision. I refer to page 6, first line, the term "borderline"is still there and should be replaced with "a" trend ..." as in the other cases.
Page 6, para 2, last line: Add ...histology of "a" grade II...
Page 6, last para, 4th line from bottom: add ...first treated for "an" anaplastic astrocytoma....

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I declare that I have no competing interests.